No profile data available.
Seaport Therapeutics, Inc. (SPTX) is a listed company, based in Boston, United States, with about 58 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$74.88 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $971.58 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Seaport Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$971.58 million as of October 9, 2026.